Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
30 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-selected-to-present-at-the-2024-american-transplant-congress-in-philadelphia-302158666.html
19 Sep 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/lyfebulb-and-veloxis-pharmaceuticals-announce-finalists-for-2022-innovation-challenge-in-organ-transplantation-301627424.html
28 Jun 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-announces-dosing-of-the-first-patient-by-partner-xenikos-in-the-global-phase-3-study-evaluating-t-guard-in-patients-with-steroid-refractory-acute-graft-versus-host-disease-sr-agvhd-301576083.html
18 May 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-announces-dosing-of-the-first-participant-in-a-phase-i-study-of-vel-101-a-novel-investigational-drug-for-kidney-transplant-immunosuppression-301549664.html
17 Feb 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/02/17/2387463/0/en/OSE-Immunotherapeutics-is-Pleased-to-Announce-that-Veloxis-Pharmaceuticals-Inc-its-Partner-in-Transplantation-has-Obtained-FDA-Fast-Track-Designation-for-CD28-Antagonist-VEL-101-FR.html
26 Apr 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/ose-immunotherapeutics-and-veloxis-pharmaceuticals-enter-into-global-license-agreement-to-develop-manufacture-and-commercialize-fr104-a-cd28-antagonist-in-the-organ-transplantation-market-301276977.html
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?